Skip to content

NEWS

Marius Nacht to invest $20m in Regenera

January 2, 2018

aMoon Partners, controlled and managed by by Check Point Software Technologies Ltd. (Nasdaq: CHKP) cofounder Marius Nacht, together with Dr. Yair Schindel, is likely to invest $20 million more in pharma company Regenera, in which InterCure Ltd. (TASE: INCR-L) owns a 23.48% stake. According to the proposal, aMoon will invest $10 million now and $10 million more as needed.

Read More

Nacht, Harel Insurance invest in personalized cancer treatment

December 7, 2017

Ayala Pharmaceuticals has bought rights from international company Bristol-Myers Squibb (BMS) to develop a personalized treatment for cancer. Ayala, founded a few months ago for this purpose, is an initiative by the Israel Biotech Fund, led by Dr. David Sidransky, Dr. Yuval Cabilly, and Ido Zairi. The fund recruited the aMoon Partners fund (led by Check…

Read More

Ayala Pharmaceuticals, Founded by Israel Biotech Fund, aMoon and Harel Insurance, Enters Exclusive Worldwide License Agreement with Bristol-Myers Squibb (BMS) to Develop Cancer Treatments

December 6, 2017

REHOVOT, Israel–(BUSINESS WIRE)–Ayala Pharmaceuticals, a biopharmaceutical company dedicated to developing targeted cancer therapies, announced today that they have entered into an exclusive worldwide license agreement with Bristol-Myers Squibb for two gamma secretase inhibitors in development for the treatment of cancers with altered Notch genes.

Read More

Mapi Pharma Ltd. Announces Closing of $10 Million Investment

August 17, 2017

Mapi Pharma Ltd., a privately held, fully integrated, clinical stage biopharmaceutical company has completed an investment round of $10 million by aMoon Fund. aMoon Fund is an Israeli investment firm focused on innovative Israeli healthcare and life science ventures, founded by Marius Nacht and Dr. Yair Schindel.

Read More

CartiHeal raises $18.3m to support PMA trial of Agili-C implant

May 8, 2017

CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects.

Read More

Israeli Universal Flu Vaccine Maker Receives $2.8 Million Investment

January 4, 2017

Israeli billionaire Marius Nacht is banking on Israeli bio-tech with a $2.8 million investment into BiondVax Pharmaceuticals, a clinical phase company developing a universal flu vaccine.

Read More

Steven Mnuchin, Israeli Health Officials Discuss Establishment of Israeli FDA Branch

October 29, 2019

The FDA, which approves all medical devices and formulations in the U.S., has very few branches outside of the U.S.

Read More

aMoon invests in $80m Adicet Bio financing round

October 3, 2019

Based on technology developed by the Technion’s Prof. Yoram Reiter, Adicet Bio is developing allogeneic cell therapies for cancer using innovative gamma delta T cells.

Read More

MDClone, Developer of First Healthcare Synthetic Data Engine, Raises $26 Million

August 22, 2019

aMoon Leads New Investment Round with Participation from OrbiMed and Lightspeed Venture Partners.

Read More

Israel’s 10 ‘Hottest’ Startups In 2019, According to WIRED Magazine

August 21, 2019

Tel Aviv – has “the highest number of startups per capita in the world…with more than 6,000, of which 18 are unicorns…more than 100 venture capital funds, plus hundreds of accelerators and co-working places.”

Read More

Nobio gets FDA approval for anti-bacterial dental fillings

August 5, 2019

TEL AVIV (Reuters) – Israel’s Nobio Ltd said on Monday it received approval from the U.S. Food and Drug Administration to market its anti-bacterial composite designed to remain in the teeth for decades.

Read More

Can This Ancient Greek Medicine Cure Humanity?

July 26, 2019

There’s fresh interest in a fabled shrub on the Aegean island of Chios.

Read More

Marius Nacht Buys Controlling Stake in Universal Flu Vaccine Developer BiondVax

July 17, 2019

Based in Jerusalem, Nasdaq-listed BiondVax develops a universal flu vaccine, currently in advanced clinical trials

Read More

First Participant Enrolled in Second Cohort of BiondVax’s Pivotal, Clinical Efficacy, Phase 3 Universal Flu Vaccine Trial

July 8, 2019

BiondVax’s M-001 universal flu vaccine candidate is designed to improve upon currently marketed strain-specific vaccines in several ways.

Read More

ArcherDX and Ayala Pharmaceuticals Announce Strategic Companion Diagnostic Collaboration

July 8, 2019

Enabling Genomically Defined Treatments for Underserved Cancers

Read More

AI triage solution for brain bleeds gains FDA clearance

June 17, 2019

Zebra Medical Vision announced Monday, June 17, that its AI solution for intracranial hemorrhage (ICH) alerts has gained FDA approval.

Read More
Scroll To Top